
    
      Study IPI-926-04 is a Phase 2, double-blind, placebo-controlled, multicenter, trial
      evaluating the safety and efficacy of IPI-926 in patients with metastatic or locally advanced
      (unresectable) chondrosarcoma. The study includes an optional cross-over to open-label
      IPI-926 for patients randomly assigned to placebo who experience documented disease
      progression.
    
  